SEARCH

SEARCH BY CITATION

References

  • 1
    Melián C, Pérez-Alenza MD, Peterson ME. Hyperadrenocorticism in dogs. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 7th ed. St. Louis, MO: Saunders-Elsevier; 2010:18161840.
  • 2
    Rijnberk A, Kooistra HS. Glucocorticoid excess. In: Schlütersche, ed. Clinical Endocrinology of Dogs and Cats. Hannover: Schlütersche Verlagsgesellschaft mbH & Co; 2010:110134.
  • 3
    Kyles AE, Feldman EC, De Cock HE, et al. Surgical management of adrenal gland tumors with and without associated tumor thrombi in dogs: 40 cases (1994–2001). J Am Vet Med Assoc 2003;223:654662.
  • 4
    Jiménez Peláez M, Bouvy BM, Dupre GP. Laparoscopic adrenalectomy for treatment of unilateral adrenocortical carcinomas: Technique, complications, and results in seven dogs. Vet Surg 2008;37:444453.
  • 5
    Schwartz P, Kovak JR, Koprowski A, et al. Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999–2005). J Am Vet Med Assoc 2008;232:7784.
  • 6
    Massari F, Nicoli S, Romanelli G, et al. Adrenalectomy in dogs with adrenal gland tumors: 52 cases (2002–2008). J Am Vet Med Assoc 2011;239:216221.
  • 7
    Kintzer PP, Peterson ME. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms. J Am Vet Med Assoc 1994;205:5461.
  • 8
    Keiser M, Fluckiger M, Gardelle O, et al. [Mitotane treatment in a dog with a recurring adrenocortical carcinoma—A case report]. Schweiz Arch Tierheilkd 1999;141:279285.
  • 9
    Eastwood JM, Elwood CM, Hurley KJ. Trilostane treatment of a dog with functional adrenocortical neoplasia. J Small Anim Pract 2003;44:126131.
  • 10
    Benchekroun G, de Fornel-Thibaud P, Lafarge S, et al. Trilostane therapy for hyperadrenocorticism in three dogs with adrenocortical metastasis. Vet Rec 2008;163:190192.
  • 11
    Helm JR, McLauchlan G, Boden LA, et al. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane. J Vet Intern Med 2011;25:251260.
  • 12
    Carr AP. Treatment of hypertension. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine, 7th ed. St. Louis, MO: Saunders-Elsevier; 2010:582585.
  • 13
    Ginel PJ, Sileo MT, Blanco B, et al. Evaluation of serum concentrations of cortisol and sex hormones of adrenal gland origin after stimulation with two synthetic ACTH preparations in clinically normal dogs. Am J Vet Res 2012;73:237241.
  • 14
    Pérez Alenza DP, Arenas C, López ML, et al. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc 2006;42:269276.
  • 15
    Feldman EC, Nelson RW, Feldman MS. Use of low- and high-dose dexamethasone tests for distinguishing pituitary-dependent from adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc 1996;209:772775.
  • 16
    Benchekroun G, de Fornel-Thibaud P, Rodriguez Piñeiro MI, et al. Ultrasonography criteria for differentiating ACTH dependency from ACTH independency in 47 dogs with hyperadrenocorticism and equivocal adrenal asymmetry. J Vet Intern Med 2010;24:10771085.
  • 17
    den Hertog E, Braakman JC, Teske E, et al. Results of non-selective adrenocorticolysis by o, p'-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 1999;144:1217.
  • 18
    Hoerauf A, Reusch C. Ultrasonographic characteristics of both adrenal glands in 15 dogs with functional adrenocortical tumors. J Am Anim Hosp Assoc 1999;35:193199.
  • 19
    Anderson CR, Birchard SJ, Powers BE, et al. Surgical treatment of adrenocortical tumors: 21 cases (1990–1996). J Am Anim Hosp Assoc 2001;37:9397.
  • 20
    Lang JM, Schertel E, Kennedy S, et al. Elective and emergency surgical management of adrenal gland tumors: 60 cases (1999–2006). J Am Anim Hosp Assoc 2011;47:428435.
  • 21
    Barker EN, Campbell S, Tebb AJ, et al. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005;19:810815.
  • 22
    Clemente M, De Andrés PJ, Arenas C, et al. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2007;161:805809.
  • 23
    Bailey CS, Page RL. Tumors of the endocrine system. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed. Edinburgh: Elsevier Saunders; 2007:583609.
  • 24
    Feldman EC, Nelson RW, Feldman MS, et al. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs. J Am Vet Med Assoc 1992;200:16421647.
  • 25
    Horauf A, Reusch C. [Effects of mitotane therapy in dogs with pituitary dependent Cushing syndrome on the adrenal gland size—An ultrasonographic study]. Schweiz Arch Tierheilkd 1999;141:239245.
  • 26
    Mantis P, Lamb CR, Witt AL, et al. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Vet Radiol Ultrasound 2003;44:682685.
  • 27
    Machida T, Uchida E, Matsuda K, et al. Aldosterone-, corticosterone- and cortisol-secreting adrenocortical carcinoma in a dog: Case report. J Vet Med Sci 2008;70:317320.
  • 28
    Peterson ME, Gilbertson SR, Drucker WD. Plasma cortisol response to exogenous ACTH in 22 dogs with hyperadrenocorticism caused by adrenocortical neoplasia. J Am Vet Med Assoc 1982;180:542544.
  • 29
    Platt SR. Neuromuscular complications in endocrine and metabolic disorders. Vet Clin North Am Small Anim Pract 2002;32:125146.
  • 30
    Culvenor J. Surgery in the treatment of canine hyperadrenocorticism. Adrenalectomy. Aust Vet J 2003;81:3435.
  • 31
    Ginel PJ, Sileo MT, Blanco B, et al. Evaluation of serum concentrations of cortisol and sex hormones of adrenal gland origin after stimulation with two synthetic ACTH preparations in clinically normal dogs. Am J Vet Res 2011;73:237241.